Lars Wagner

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. ncbi Reducing irinotecan-associated diarrhea in children
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:201-7. 2008
  2. ncbi Malignant rhabdoid tumor mimicking hepatoblastoma: a case report and literature review
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Pediatr Dev Pathol 10:409-15. 2007
  3. ncbi Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Pediatr Hematol Oncol 28:635-41. 2006
  4. ncbi Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma
    Lars M Wagner
    Division of Hematology Oncology, Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Blood Cancer 48:132-9. 2007
  5. ncbi Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study
    Lars M Wagner
    Department of Hematology Oncology Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229, USA
    J Clin Oncol 27:1290-6. 2009
  6. ncbi Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Lars M Wagner
    Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Cancer Res 10:840-8. 2004
  7. ncbi Spinal cord schwannomas mimicking drop metastases in a patient with intramedullary ependymoma and neurofibromatosis 2
    Lars M Wagner
    Department of Pediatrics, University of Utah, Primary Children s Medical Center, Salt Lake City, Utah, USA
    J Pediatr Hematol Oncol 26:56-9. 2004
  8. ncbi Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 54:538-45. 2010
  9. ncbi A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Hematol Oncol 33:316-9. 2011
  10. ncbi Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 13:5418-25. 2007

Research Grants

  1. Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
    Lars Wagner; Fiscal Year: 2007

Detail Information

Publications17

  1. ncbi Reducing irinotecan-associated diarrhea in children
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:201-7. 2008
    ..This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan...
  2. ncbi Malignant rhabdoid tumor mimicking hepatoblastoma: a case report and literature review
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Pediatr Dev Pathol 10:409-15. 2007
    ..Important similarities and differences between hepatoblastoma and rhabdoid tumors are reviewed, and suggestions are offered to help distinguish these 2 tumor types...
  3. ncbi Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Pediatr Hematol Oncol 28:635-41. 2006
    ..The selective expression of MYCN in tumor cells, and the sensitivity of detection of MYCN by RT-PCR noted in this and other studies, supports further evaluation of MYCN as a NB marker for molecular detection of minimal residual disease...
  4. ncbi Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma
    Lars M Wagner
    Division of Hematology Oncology, Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Blood Cancer 48:132-9. 2007
    ..Because responses were seen in patients with Ewing sarcoma (ES) on that trial, additional patients were treated with this combination following study completion...
  5. ncbi Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study
    Lars M Wagner
    Department of Hematology Oncology Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229, USA
    J Clin Oncol 27:1290-6. 2009
    ....
  6. ncbi Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    Lars M Wagner
    Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Cancer Res 10:840-8. 2004
    ..The purpose is to estimate the maximum-tolerated dose (MTD) of temozolomide and irinotecan given on a protracted schedule in 28-day courses to pediatric patients with refractory solid tumors...
  7. ncbi Spinal cord schwannomas mimicking drop metastases in a patient with intramedullary ependymoma and neurofibromatosis 2
    Lars M Wagner
    Department of Pediatrics, University of Utah, Primary Children s Medical Center, Salt Lake City, Utah, USA
    J Pediatr Hematol Oncol 26:56-9. 2004
    ....
  8. ncbi Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 54:538-45. 2010
    ..Patients received orally administered irinotecan together with temozolomide and vincristine on two different schedules, using cefixime to reduce irinotecan-associated diarrhea...
  9. ncbi A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma
    Lars M Wagner
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Hematol Oncol 33:316-9. 2011
    ..The possibility of benign etiologies for soft tissue masses should be considered when planning surgical options, even when preoperative imaging studies suggest more aggressive lesions...
  10. ncbi Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 13:5418-25. 2007
    ..We hypothesized that the DNA repair protein methylguanine-DNA methyltransferase (MGMT) is an important resistance factor, and that inactivation of MGMT would sensitize neuroblastoma cells to these agents...
  11. ncbi Treatment of metastatic rhabdoid tumor of the kidney
    Lars Wagner
    Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA
    J Pediatr Hematol Oncol 24:385-8. 2002
    ..Alternating courses of ICE and VDC have activity against metastatic RTK. This combination of agents warrants prospective investigation in clinical trials...
  12. ncbi The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations
    Kasiani Myers
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Pediatr Blood Cancer 58:462-5. 2012
    ....
  13. ncbi Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients
    Lars M Wagner
    Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 62:5001-7. 2002
    ..Assessment of purging efficacy with additional samples from NB patients is ongoing...
  14. ncbi Fetus in fetu: unexpected cause of an abdominal mass
    Lars Wagner
    Department of Pediatrics, Division of Hematology/Oncology, Primary Children's Medical Center, University of Utah, 100 N. Medical Drive, Salt Lake City, UT 84113, USA
    J Pediatr Hematol Oncol 24:779-80. 2002
  15. ncbi Extralobar pulmonary sequestration presenting with torsion: a case report and review of literature
    Wendy Chen
    Department of Pediatric General and Thoracic Surgery, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    J Pediatr Surg 46:2025-8. 2011
    ..Although radiologic findings of a systemic arterial supply to the mass may be absent, with patients presenting with this constellation of symptoms, a high index of suspicion of a sequestration should be maintained...
  16. ncbi Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial
    Lars M Wagner
    Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 22:1886-93. 2004
    ..CONCLUSION: The addition of EPO to the G-CSF regimen provides no benefit for patients receiving intensive induction chemotherapy for high-risk neuroblastoma...
  17. ncbi New therapeutic targets for the treatment of high-risk neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Cell Biochem 107:46-57. 2009
    ..In this review we summarize ongoing clinical trials and highlight new developments in our understanding of the molecular biology of neuroblastoma, emphasizing potential targets or pathways that may be exploitable therapeutically...

Research Grants1

  1. Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
    Lars Wagner; Fiscal Year: 2007
    ..We hypothesize this strategy will be well tolerated and allow for meaningful dose escalation through chemoprotection afforded by gene transfer into hematopoietic stem cells. ..